PharmaIN is a clinical stage biopharmaceutical company pioneering first- and best-in-class subcutaneous therapies through thoughtful peptide engineering. Leveraging its expertise in target-specific biology, peptide drug design, and innovative drug delivery, PharmaIN is focused on developing novel treatments for patients with advanced liver cirrhosis and cancer.
PharmaIN is revolutionizing the treatment landscape with our innovative pipeline of peptide-based, self-injectable therapies. With a commitment to improving quality of life, our drug development programs target chronic and complex conditions and are designed to provide solutions that enable patients to manage their health more effectively and independently.
PHIN-214 is an optimized vasopressor therapy targeting a clinically validated mechanism of action enabling safe, subcutaneous administration and broad application for the prevention and treatment of decompensated cirrhosis. PharmaIN is currently enrolling patients in its ongoing Phase 1 clinical trial evaluating PHIN-214 in advanced liver cirrhosis.
PharmaIN is actively seeking a strategic partner to advance PHIN-214 through clinical development and commercialization.